



PRESS RELEASE

to-BBB secures grant from the Sanfilippo Syndrome Medical Research Foundation, Inc.

Leiden, The Netherlands - October 20, 2005 - The Dutch biotechnology company to-BBB announced today that it has received a \$100,000 grant from the Sanfilippo Syndrome Medical Research Foundation, Inc (USA). The grant supports the preclinical project “Targeting sulphamidase to the brain”. This project involves the replacement of defective sulphamidase enzyme in the brain that leads to severe neurological disorders (Sanfilippo Syndrome; MPS IIIA), particularly in children. In this project there will be a collaboration with Dr A.G. de Boer from Leiden University and Prof. W.A. Banks, MD, and Prof. W.S. Sly, MD, both from St. Louis University School of Medicine, USA. The investigations are planned for one year and concern the application of to-BBB's drug targeting technology 2B-Trans™ to target sulphamidase to the brain.

About 2B-Trans™ technology

The central nervous system (CNS) drug market is a rapidly growing market with many unmet medical needs. However, many potential CNS drugs cannot enter the brain due to the presence of the neuroprotective blood-brain barrier. to-BBB developed the unique CNS drug targeting solution 2B-Trans™ that delivers drugs into the CNS after an intravenous injection, without disruption of the blood-brain barrier. The proprietary 2B-Trans™ technology uses a well characterized and effective transport system with a specific carrier protein that has an excellent proven safety profile in humans.



About Sanfilippo Syndrome Medical Research Foundation, Inc.

The Sanfilippo Syndrome Medical Research Foundation, Inc. (SSMRF) is a non-profit organization promoting research toward a cure for Sanfilippo Syndrome Type A, and related neurodegenerative disorders. SSMRF was incorporated under the laws of the State of Nebraska (USA) in November of 2000. For additional information please visit www.juliashope.org

About to-BBB technologies BV

to-BBB, founded in 2003, is a spin-off company from the renowned Blood-Brain Barrier Research Group of Leiden University in The Netherlands. to-BBB is located at the Bio-Science Park in Leiden.

to-BBB has recently announced a collaboration agreement with Biogen Idec and an evaluation and licence option agreement with Genmab and has signed a research agreement with another undisclosed US based top 5 biotech company. to-BBB is currently negotiating agreements with several other companies, who will be offered access to the 2B-Trans™ technology. For additional information about the company, please visit www.toBBB.com.

For further information please contact:

Alfred N. Nijkerk, PharmD, CBO

Tel: +31 6 55128387

Fax: +31 84 8709728

E-mail: Nijkerk@toBBB.com

Website: www.toBBB.com